Pfizer heads to the FDA with an early lead over rivals in the $10B RSV vaccine market

The 50-year race to develop an RSV vaccine turned a corner on Thursday with Pfizer unveiling promising pivotal data for its bivalent RSV vaccine candidate, promising to take the data to the FDA ahead of several rivals in a market that could stretch to $10 billion by 2030.